Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 38 results found. Search for [ Nexavar ]

Results 1 to 21 of 38
Prasanna Mohanty
July 27, 2020
Profit-driven enterprises are ill-suited to protect the health and life of a vast majority of people, as the US and Indian governments experience, but do precious little, thereby failing in their primary duty


E Kumar Sharma
June 3, 2016
\"Real, meaningful progress remains elusive, and recent signals indicate backsliding in key areas. For instance, India just released its long-awaited National Intellectual Property Rights Policy, which falls far short of industry expectations.\"


Aprajita Sharma
New Delhi, January 5, 2016
Analysts believe first half of 2016 may mirror bearish trend of 2015, but benchmark indices may begin to log gains in the second half of 2016.


PTI
New Delhi, November 17, 2015
The Swiss drug major said that a highly predictable IPR regime is needed for the Indian pharma industry to develop to the level of the US or Europe.


E. Kumar Sharma
April 28, 2015
One leading industry representative saw in the PM's statement \"a clear signal to bureaucracy not to resist TRIPs Plus measures such as Patent Linkage, Data Exclusivity, Dilution of Section 3(d) and Declaration of No-use of compulsory license.\"


P.B. Jayakumar
March 5, 2015
The US is mounting pressure on India to agree to its terms in pharma IP protection. How long can India resist?


E Kumar Sharma
January 17, 2015
The Indo-US talks in January, to be held just days before President Barack Obama visits India to attend the Republic Day celebrations, are part of a work plan on IPR agreed upon by both nations in November.


E Kumar Sharma
December 18, 2014
Experts say the Novartis-Cipla case raises similar issues that previous cases did - non-availability of drugs, non-working of patent in India and unaffordable pricing.


Manoj Kumar
May 1, 2014
Commerce Secretary Rajeev Kher praised a decision by the US Trade Representative not to label India with its worst offender tag in an annual scorecard on protecting U.S. patents, copyrights and other intellectual property.


Mail Today Bureau
New Delhi, March 24, 2014
Commerce and industry minister Anand Sharma on Sunday came out strongly to defend India's track record on intellectual property rights and said that the country is ready to take on the US at the World Trade Organization (WTO) over the issue.


Sumeet Chatterjee and Ben Hirschler
Mumbai/London, February 6, 2014
Global pharmaceutical firms are pressuring the United States to act against India to stop more local companies producing up to a dozen new varieties of cheap generic drugs still on-patent.


PTI
New Delhi, August 28, 2013
In reply to allegations made by Novartis on India's 'discriminatory' patent practices, the government has said global firms have benefited more from the country's rules than suffer from them.


E. Kumar Sharma
April 13, 2013
The Supreme Court decision on Glivec sets the tone for other patent disputes and puts global drugmakers on the back foot.


BT Online Bureau
New Delhi, April 1, 2013
The Intellectual Property Appellate Board had denied the patent right for the drug to Novartis in 2006. The Swiss pharma major had in 2009 taken its challenge against a law that bans patents on newer forms of known drugs to the Supreme Court.


E Kumar Sharma
March 28, 2013
Novartis and many companies see the final decision on Glivec, whose generic versions are currently sold in the Indian market, as a landmark judgment for it would bring clarity on the interpretation and implementation of the Indian Patents Act.


BT Online Bureau
March 7, 2013
Bayer AG  will approach the high court in Mumbai against a ruling by Intellectual Property Appellate Board that upheld the compulsory licence issued to India's Natco Pharma to make and sell a low-cost generic of the German drug major's patented cancer drug Nexavar.


Associated Press
New Delhi, March 5, 2013
The Intellectual Property Appellate Board has rejected Bayer AG's plea to stop Natco Pharma from producing a cheaper generic version of its patented cancer drug.


BT Online Bureau
New Delhi, January 26, 2013
Biocon is eyeing Rs 100 cr in sales in the next four years from psoriasis drug that it plans to launch under the brand Alzumab in the country in the current year.


E. Kumar Sharma
January 29, 2013
Millions of Indians are grappling with the costs of cancer treatment, sometimes spending their life's savings on it.


PTI
December 11, 2012
Indian Patents Office has revoked a patent for an asthma drug held by US-based Merck & Co following a challenge from domestic pharma firm Cipla.


PAGES 1 OF 2  12